Uniqure NV (NASDAQ:QURE) – Analysts at Svb Leerink issued their Q1 2020 EPS estimates for shares of Uniqure in a research note issued on Tuesday, July 30th. Svb Leerink analyst J. Schwartz expects that the biotechnology company will earn ($0.82) per share for the quarter. Svb Leerink also issued estimates for Uniqure’s Q2 2020 earnings at ($0.81) EPS, Q3 2020 earnings at ($0.83) EPS and Q4 2020 earnings at ($0.84) EPS.
Uniqure (NASDAQ:QURE) last posted its earnings results on Monday, July 29th. The biotechnology company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.08). The company had revenue of $2.47 million during the quarter, compared to the consensus estimate of $1.53 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%.
QURE stock opened at $59.96 on Wednesday. The company has a market capitalization of $2.48 billion, a PE ratio of -25.62 and a beta of 1.05. The company has a debt-to-equity ratio of 0.38, a current ratio of 9.51 and a quick ratio of 9.51. Uniqure has a 12 month low of $21.98 and a 12 month high of $82.49. The business has a 50-day moving average of $72.71.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $71.45, for a total transaction of $571,600.00. Following the completion of the sale, the chief executive officer now owns 404,839 shares of the company’s stock, valued at approximately $28,925,746.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Philip Astley-Sparke sold 6,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $63.63, for a total value of $381,780.00. Following the transaction, the director now owns 18,872 shares in the company, valued at $1,200,825.36. The disclosure for this sale can be found here. Insiders have sold a total of 30,000 shares of company stock valued at $2,040,020 in the last three months. Insiders own 2.91% of the company’s stock.
Several institutional investors have recently bought and sold shares of QURE. Vivo Capital LLC bought a new position in shares of Uniqure during the 1st quarter worth approximately $10,757,000. OppenheimerFunds Inc. lifted its holdings in shares of Uniqure by 5.2% in the 1st quarter. OppenheimerFunds Inc. now owns 1,817,534 shares of the biotechnology company’s stock worth $108,416,000 after purchasing an additional 90,391 shares in the last quarter. FIL Ltd lifted its holdings in shares of Uniqure by 23.3% in the 1st quarter. FIL Ltd now owns 419,392 shares of the biotechnology company’s stock worth $25,017,000 after purchasing an additional 79,209 shares in the last quarter. First Trust Advisors LP bought a new position in shares of Uniqure in the 2nd quarter worth $3,666,000. Finally, Sanders Morris Harris LLC bought a new position in shares of Uniqure in the 2nd quarter worth $3,084,000. Hedge funds and other institutional investors own 60.27% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.